8-K current report · filed Oct 8, 2026

Editas Medicine, Inc. (EDIT) 8-K Current Report: October 8, 2026

Item 8.01Item 7.01EDIT overview

Short answer

Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). FDA approval to initiate first-in-human EDIT-401 trial in hyperlipidemia.

Editas Medicine, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA approval to initiate first-in-human EDIT-401 trial in hyperlipidemia
  • Clinical-stage milestone enabling initial human safety and efficacy testing
  • EDIT-401 trial start creates development catalyst, with future value dependent on clinical results

Item 8.01 · Other Events

  • Australia approval enables Phase 1/2 Strive trial of EDIT-401 in heterozygous familial hypercholesterolemia
  • EDIT-401 targets LDLR upregulation, with approximately 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates
  • Approximately 90% LDL-C reduction maintained over 10 months in ongoing non-human primate study
  • Initial safety and tolerability data expected in Q1 2027, with Part 1 topline data later in 2027
  • New Zealand approval remains pending, creating enrollment and execution uncertainty

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Editas Medicine, Inc. 8-K filings

Get the next EDIT 8-K as it lands

Follow EDIT for push alerts, or ask the research agent what this filing means.